Atara Biotherapeutics, Inc. (NASDAQ:ATRA) CAO Yanina Grant-Huerta Sells 2,218 Shares

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) CAO Yanina Grant-Huerta sold 2,218 shares of the stock in a transaction on Friday, May 16th. The shares were sold at an average price of $6.76, for a total value of $14,993.68. Following the sale, the chief accounting officer now owns 37,067 shares of the company’s stock, valued at approximately $250,572.92. This represents a 5.65% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Atara Biotherapeutics Price Performance

Shares of ATRA stock traded up $0.27 during trading on Tuesday, hitting $7.00. 75,613 shares of the stock traded hands, compared to its average volume of 124,406. Atara Biotherapeutics, Inc. has a 52-week low of $5.01 and a 52-week high of $18.71. The firm has a market capitalization of $41.73 million, a P/E ratio of -0.27 and a beta of 0.30. The firm’s fifty day moving average price is $6.65 and its 200-day moving average price is $9.15.

Atara Biotherapeutics (NASDAQ:ATRA) last issued its quarterly earnings data on Thursday, May 15th. The biotechnology company reported $3.50 EPS for the quarter, topping the consensus estimate of ($3.07) by $6.57. The company had revenue of $98.10 million during the quarter, compared to analyst estimates of $4.30 million. As a group, equities research analysts expect that Atara Biotherapeutics, Inc. will post -10.39 earnings per share for the current year.

Analysts Set New Price Targets

Several analysts have weighed in on the company. Canaccord Genuity Group reiterated a “buy” rating and set a $17.00 price target on shares of Atara Biotherapeutics in a research note on Tuesday, March 11th. RODMAN&RENSHAW downgraded shares of Atara Biotherapeutics from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 21st. Finally, HC Wainwright restated a “neutral” rating on shares of Atara Biotherapeutics in a research note on Tuesday, January 28th. One analyst has rated the stock with a sell rating, three have assigned a hold rating, three have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $17.75.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. EcoR1 Capital LLC increased its stake in shares of Atara Biotherapeutics by 7.7% during the first quarter. EcoR1 Capital LLC now owns 573,183 shares of the biotechnology company’s stock worth $3,405,000 after buying an additional 41,049 shares during the period. Staley Capital Advisers Inc. grew its holdings in Atara Biotherapeutics by 60.0% during the 1st quarter. Staley Capital Advisers Inc. now owns 80,000 shares of the biotechnology company’s stock worth $475,000 after acquiring an additional 30,000 shares in the last quarter. Marshall Wace LLP purchased a new stake in shares of Atara Biotherapeutics in the 4th quarter valued at approximately $332,000. Birchview Capital LP acquired a new stake in shares of Atara Biotherapeutics in the 4th quarter valued at $293,000. Finally, Cubist Systematic Strategies LLC purchased a new stake in shares of Atara Biotherapeutics during the 4th quarter worth $169,000. 70.90% of the stock is currently owned by hedge funds and other institutional investors.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.